Sorrento Therapeutics shares are trading higher after the company received FDA IND clearance to initiate the Phase I clinical trial of its CD38 antibody-drug conjugate STI-6129 for patients with amyloidosis.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!